Omeros shares gain on positive Phase IIb data. Pozen licenses migraine drug to JNJ in South America. After the bell: MediciNova slumps on offering Print
By Staff and Wire Reports   
Wednesday, 23 March 2011 18:36
Below is a look at some of the headlines for companies that made news in the healthcare sector on March 23, 2011.

After the bell, shares of MediciNova, Inc.(Nasdaq:MNOV) slumped after the company announced it will sell 2.7 million shares at $3.00 per share for gross proceeds of $8.25 million. In extended trading shares fell 52 cents or 14% to $3.04.

Shares of Omeros Corporation (Nasdaq:OMER), surged today after the company reported positive data from a Phase 2b clinical trial evaluating OMS302 in patients undergoing cataract surgery. OMS302, added to standard irrigation solution used during ophthalmological procedures, is Omeros' proprietary PharmacoSurgery product in development to maintain intra-operative mydriasis (pupil dilation) and reduce postoperative pain and irritation resulting from cataract and other lens replacement surgery.

Shares gained 64 cents or 10.58% to $6.69.

Shares of POZEN Inc. (NASDAQ:POZN), moved higher after the company announced that it has entered into a license agreement with Cilag GmbH International, a division of Johnson & Johnson, for the development and commercialization of MT 400 in Brazil, Colombia, Ecuador and Peru. MT 400 is POZEN’s proprietary combination of sumatriptan and naproxen sodium, the first multiple mechanism triptan therapy for the treatment of migraine. POZEN previously licensed U.S.-only rights to MT 400 to GlaxoSmithKline, who markets a different dose of MT 400 as Treximet.

Shares were up 18 cents or 4% to $4.93.

Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the Phase III clinical trial of its investigational antiretroviral agent elvitegravir, a novel oral integrase inhibitor being evaluated for the treatment of HIV-1 infection in treatment-experienced patients, met its primary objective. The primary endpoint of this study was non-inferiority at week 48 of elvitegravir, dosed once daily, compared to raltegravir, dosed twice daily, each administered with a background regimen that includes a ritonavir-boosted protease inhibitor (PI) and a second antiretroviral agent.

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), today announced that it has enrolled 33 percent of the total projected patients required for its Phase IIb clinical trial of Serdaxin to treat major depressive disorder (MDD). The study calls for enrollment of up to 300 patients and is being conducted at approximately 40 sites in the United States. Enrollment for the Phase IIb trial was initiated in January 2011. "We are pleased with the rapid progress we are making in Serdaxin’s Phase IIb trial enrollment," said Rick Soni, President of Rexahn. "We remain on track to complete enrollment in the first half of 2011, with preliminary results expected in late 2011."

Also Wednesday:

AdCare Health Systems, Inc. (NYSE Amex: ADK) , a leading skilled nursing and assisted living provider, reported unaudited financial results for the fourth quarter and fiscal year ended December 31, 2010.

Allezoe Medical Holdings (OTCBB:ALZM) today announced the additional members of its wholly-owned subsidiary Organ Transport Systems' Medical Advisory Board.

Healthnostics, Inc. (PINKSHEETS: HNSS) issued U.S. News Company a six month option to purchase 10 million shares of Healthnostics, Inc. common stock at $.015 per share and a one-year option to purchase an additional 10 million shares at $.03 per share.

Leatt Corporation, a Nevada corporation (PINKSHEETS:LEAT) (Company), and the developer of the Leatt-Brace®, a Neck Brace System designed to help prevent potentially devastating motor sport injuries to the neck, today announced the release of its Leatt® STX Road, the all-new neck brace specifically for street motorcycle riders.

Ophthalmic Imaging Systems (OIS) (OTCBB: OISI), a leading ophthalmic digital imaging and informatics company, today announced that it will restate its financial results as of and for the fiscal year ended December 31, 2009 included in its Annual Report on Form 10-K, and its interim financial results as filed on Form 10-Q for periods ending March 31, June 30 and September 30, 2010 and 2009.

Power of the Dream Ventures, Inc. (OTCBB:PWRV), Hungary's premier technology commercialization company, is pleased to announce the signing of an Investment Agreement with Genetic Immunity, one of the leaders of therapeutic vaccine product development.

Sionix Corporation (OTCBB: SINX), designer of innovative and patented, advanced mobile water treatment systems, is pleased to announce that it has entered into an agreement with SAJ Consult LLC (SAJC) of Las Vegas, NV to represent certain Sionix interests in the People's Republic of China (PRC) and other countries in South and Southeast Asia.


"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus